ARQT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
143.9M
+10.8%
129.9M
+23.2%
105.4M
-18.6%
129.5M
+30.5%
99.2M
Cost of Revenue
12.5M
+13.9%
10.9M
+11.8%
9.8M
-16.3%
11.7M
+34.6%
8.7M
Gross Profit
131.5M
+10.5%
118.9M
+24.4%
95.6M
-18.8%
117.8M
+30.1%
90.5M
Operating Expenses
122.0M
+19.1%
102.5M
-2.1%
104.7M
+5.3%
99.4M
+21.2%
82.0M
R&D
22.4M
+10.2%
20.4M
-33.5%
30.6M
+49.8%
20.5M
+4.3%
19.6M
SG&A
99.6M
+21.3%
82.1M
+10.9%
74.1M
-6.2%
79.0M
+26.6%
62.4M
Operating Income
9.4M
-42.6%
16.4M
+280.8%
-9089000
-149.4%
18.4M
+115.7%
8.5M
EBITDA
11.1M
-29.9%
15.9M
+286.1%
-8527000
-159.7%
14.3M
+13.1%
12.6M
Net Income
8.8M
-41.4%
15.0M
+232.9%
-11295000
-164.9%
17.4M
+134.8%
7.4M
EPS (Basic)
$0.07
-36.4%
$0.11
+222.2%
$-0.09
-164.3%
$0.14
+133.3%
$0.06
EPS (Diluted)
$0.06
-45.5%
$0.11
+222.2%
$-0.09
-164.3%
$0.14
+133.3%
$0.06
Shares (Diluted)
136.8M
+0.7%
135.9M
+5.1%
129.4M
+5.2%
123.0M
-7.4%
132.9M
Arcutis Biotherapeutics (ARQT) — Financials